Personal Research Database Bibliometric

Full Text: 2014\Tum Bio35, 213.pdf

Abstract: Studies investigating the association between genetic polymorphism of glutathione S-transferase T1 (GSTT1) and hepatocellular carcinoma (HCC) risk have reported conflicting results. Therefore, we conducted this meta-analysis to provide more precise evidence. Databases including PubMed, Embase, SCOPUS, ISI Web of Science, and Wangfang were searched for relevant studies. Potential sources of heterogeneity were also assessed by subgroup analysis. Funnel plots and Egger’s linear regression were used to test publication bias among the articles. Finally, a total of 28 studies involving 3,897 HCC patients and 6,117 controls were included in this meta-analysis. In a combined analysis, the summary odds ratio for HCC of the GSTT1 null genotype was 1.43 (95 % confidence interval (CI) 1.22-1.68, P < 10(-5)). In the subgroup analysis by ethnicity, significantly increased risks were found in East Asians for GSTT1 null polymorphism, while no significant associations were found among Caucasian, South Asian, and African populations. When stratified by a source of controls, both population- and hospital-based studies get consistent positive results. By pooling data from 10 studies (1,639 cases and 2,224 controls) that considered combinations of GSTT1 and GSTM1 genotypes, a statistically significant increased risk for HCC (odd ratio = 1.85, 95 % CI 1.37-2.49) was detected for individuals with combined deletion mutations in both genes compared with positive genotypes. No evidence of publication bias was observed. Our result suggests that the GSTT1 null genotype contributes to an increased risk of HCC in East Asians and that interaction between unfavorable GSTs genotypes may exist.

Keywords: Analysis, Asian, Association, Benzene, Bias, Carcinoma, Caucasian, Confidence, Data, Databases, Deletion, Ethnicity, Evidence, Genes, Genetic, Genetic Polymorphisms, Glutathione, Glutathione-S-Transferase, Gstm1, Gstt1, Hepatitis-C Virus, Hepatocellular Carcinoma, Heterogeneity, Interaction, Interval, Isi, Isi Web of Science, Linear Regression, Meta Analysis, Meta-Analysis, Metaanalysis, Microsomal Epoxide Hydrolase, Mutations, Nested Case-Control, Odds Ratio, P, Patients, Polymorphism, Population, Populations, Primary Liver-Cancer, Publication, Publication Bias, Pubmed, Regression, Risk, Risks, Science, Scopus, Source, Sources, Susceptibility, T1, Web of Science

? Cai, Q.L., Wang, Z., Zhang, W., Guo, X.M., Shang, Z.Q., Jiang, N., Tian, J. and Niu, Y.J. (2014), Association between glutathione S-transferases M1 and T1 gene polymorphisms and prostate cancer risk: A systematic review and meta-analysis. Tumor Biology, 35 (1), 247-256.

Full Text: 2014\Tum Bio35, 247.pdf

Abstract: Genetic polymorphisms in glutathione S-transferases M1 (GSTM1) and T1 (GSTT1) genes have been widely reported and considered to have a significant effect on prostate cancer (PCa) risk, but the results are inconsistent. To evaluate the impact of the GSTM1 and GSTT1 polymorphism on PCa risk, we conducted a comprehensive meta-analysis based on 18 eligible studies. A total of 18 studies, including 7,119 subjects for GSTM1 and 6,454 subjects for GSTT1 between 1999 and 2012 were identified through researching MEDLINE, PubMed, Web of Science, EMBASE, Chinese National Knowledge Infrastructure database, and Chinese Biomedical Literature database. A meta-analysis was performed to obtain summary-estimated odd ratios and 95 % confidence intervals of GSTM1 and GSTT1 polymorphisms for PCa, with attention to study quality and publication bias. Overall, there is a significant association between GSTM1 (odds ratio (OR) = 1.407, 95 % confidence intervals (95 % CI) = 1.147-1.727, I (2) = 73.2 %, P = 0.001) genotypes and PCa susceptibility. Significant associations were also observed in subgroups of Caucasian populations (OR = 1.262, 95 % CI = 1.055-1.511, I (2) = 48.7 %, P = 0.011) and Asian populations (OR = 1.776, 95 % CI = 1.134-2.781, I (2) = 83.4 %, P = 0.012). However, no significant association was found (OR = 1.776, 95 % CI = 1.134-2.781, P = 0.243) in African-American populations when stratified by ethnicity. While, there was no significant association seen between GSTT1 (OR = 1.003, 95 % CI = 0.823-1.298, I (2) = 68.8 %, P = 0.778) genotypes and PCa risk. However, no significant associations were observed in subgroups of Caucasian populations (OR = 1.086, 95 % CI = 0.801-1.471, I (2) = 72.1 %, P = 0.597) and Asian populations (OR = 0.961, 95 % CI = 0.644-1.434, I (2) = 73.0 %, P = 0.846), and similar result was found among African-American populations (OR = 0.802, 95 % CI = 0.194-3.321, P = 0.761) when stratified by ethnicity. Our results suggest that the GSTM1 gene polymorphism contributes to PCa susceptibility, while GSTT1 gene polymorphism is not associated with PCa in our study.

Keywords: African American, Asian, Association, Attention, Bias, Biomedical, Cancer, Caucasian, Chinese, Confidence, Confidence Intervals, Database, Embase, Ethnicity, Gene, Gene Polymorphism, Genes, Glutathione, Glutathione S-Transferases M1, Glutathione S-Transferases T1 Polymorphism, Gstm1, Gstp1, Gstt1, Hyperplasia, Impact, Intervals, Knowledge, Literature, M1, Medline, Meta Analysis, Meta-Analysis, Metaanalysis, Molecular Epidemiology, North Indian Population, Odds Ratio, P, P1 Polymorphisms, Pca, Polymorphism, Polymorphisms, Populations, Prostate Cancer, Publication, Publication Bias, Pubmed, Quality, Review, Risk, Science, Smoking, Susceptibility, Systematic Review, T1, Variants, Web of Science

? Li, K., Li, W.S., Zou, H.W. and Zhao, L. (2014), Association between FAS 1377G > A polymorphism and breast cancer susceptibility: A meta-analysis. Tumor Biology, 35 (1), 351-356.

Full Text: 2014\Tum Bio35, 351.pdf

Abstract: Published studies on the association between FAS 1377G > A polymorphism and breast cancer susceptibility were inconclusive. To derive a more precise assessment of the association, a meta-analysis of published studies was performed. PubMed, Embase, and Web of Science were searched for eligible studies on the association between FAS 1377G > A polymorphism and breast cancer susceptibility. Five studies with a total of 2,905 cases and 3,090 controls were included into the meta-analysis. Overall, FAS 1377G > A polymorphism was significantly associated with increased susceptibility to breast cancer (for AA versus GG: odds ratio (OR) = 1.39, 95 % confidence interval (95 % CI) 1.12-1.72, P = 0.003; for AA/GA versus GG: OR = 1.18, 95 % CI 1.06-1.32, P = 0.004; for AA versus GG/GA: OR = 1.28, 95 % CI 1.05-1.56, P = 0.015). Subgroup analysis by ethnicity found that FAS 1377G > A polymorphism was significantly associated with increased susceptibility to breast cancer in Asians (for AA versus GG: OR = 1.48, 95 % CI 1.16-1.89, P = 0.001; for AA/GA versus GG: OR = 1.24, 95 % CI 1.06-1.46, P = 0.008; for AA versus GG/GA: OR = 1.35, 95 % CI 1.08-1.69, P = 0.008), but the association was not found in Caucasians. Therefore, the findings of the meta-analysis suggest that FAS 1377G > A polymorphism is significantly associated with increased susceptibility to breast cancer in Asians.

Keywords: Analysis, Apoptosis, Assessment, Association, Breast Cancer, Cancer, Confidence, Ethnicity, Fas, Genes Fas, Interval, Meta Analysis, Meta-Analysis, Metaanalysis, Odds Ratio, P, Polymorphism, Population, Pubmed, Risk, Science, Web of Science

? Yi, S.M. and Li, G.Y. (2014), The association of SIPA1 gene polymorphisms with breast cancer risk: Evidence from published studies. Tumor Biology, 35 (1), 441-445.

Full Text: 2014\Tum Bio35, 441.pdf

Abstract: Previous studies have focused on the association of signal-induced proliferation associated 1 gene (SIPA1) with carcinogenesis of many cancers, including breast cancer. It has been suggested that SIPA1 polymorphisms are associated with susceptibility to breast cancer. In the present study, we performed a meta-analysis to systematically summarize the possible association between SIPA1 and the risk for breast cancer. We conducted a search of case-control studies on the associations of SPIA1 with susceptibility to breast cancer in PubMed, Embase, International Statistical Institute Web of Science, Wanfang Database in China, and Chinese National Knowledge Infrastructure databases. Data from eligible studies were extracted for meta-analysis. Breast cancer risk associated with SIPA1 was estimated by pooled odds ratios and 95 % confidence intervals. Four studies on SIPA1 and breast cancer were included in our meta-analysis. Our results showed that rs746429 was associated with the risk of breast cancer. However, rs931127 and rs3741378 were not found to be associated with breast cancer in our analysis. This meta-analysis suggests that rs746429 is associated with the risk of breast cancer. Well-designed studies with larger sample size and more ethnic groups are required to further validate the results.

Keywords: Analysis, Association, Breast, Breast Cancer, Breast Cancer Risk, Cancer, Candidate, Case-Control, Case-Control Studies, China, Chinese, Confidence, Confidence Intervals, Database, Databases, Ethnic Groups, Evidence, Gene, Groups, Intervals, Knowledge, Meta Analysis, Meta-Analysis, Metaanalysis, Polymorphisms, Population, Proliferation, Pubmed, Risk, Sample Size, Science, Sipa1, Size, Web of Science

? Liu, B.J. and Shen, T. (2014), XRCC1 Arg399Gln polymorphism is not associated with oral cancer risk: Evidence from a meta-analysis. Tumor Biology, 35 (1), 507-512.

Full Text: 2014\Tum Bio35, 507.pdf

Abstract: Previous studies regarding the association between X-ray repair cross-complementing group 1 (XRCC1) Arg399Gln polymorphism and oral cancer risk were contradictory. We performed a meta-analysis to derive a more precise estimation of the association. The PubMed and Web of Science were searched for eligible studies. Odds ratio (OR) with its 95 % confidence interval (95 % CIs) was used to assess the strength of the association. Nine individual studies with a total of 3,244 subjects were finally included into the meta-analysis. Overall, there was no association between XRCC1 Arg399Gln polymorphism and oral cancer risk under all genetic models (Gln versus Arg: OR = 1.09, 95 % CI 0.86-1.37, P = 0.46; GlnGln versus ArgArg: OR = 1.11, 95 % CI 0.69-1.79, P = 0.66; GlnGln versus ArgArg/ArgGln: OR = 1.04, 95 % CI 0.68-1.61, P = 0.84; and GlnGln/ArgGln versus ArgArg: OR = 1.13, 95 % CI 0.88-1.44, P = 0.34). After excluding studies on oral leukoplakia, there was still no association between XRCC1 Arg399Gln polymorphism and oral cancer risk under all genetic models. Subgroup analysis by ethnicity suggested that there was no association between XRCC1 Arg399Gln polymorphism and oral cancer risk in both Asians and Caucasians. In conclusion, the data from the meta-analysis suggests that XRCC1 Arg399Gln polymorphism is not associated with oral cancer risk.

Keywords: Analysis, Arg194trp, Association, Cancer, Confidence, Data, Dna-Repair Genes, Ethnicity, Evidence, Genetic, Interval, Leukoplakia, Lung-Cancer, Meta Analysis, Meta-Analysis, Metaanalysis, Models, Oral, Oral Cancer, P, Polymorphism, Pubmed, Risk, Science, Single-Nucleotide Polymorphisms, Squamous-Cell Carcinoma, Strength, Susceptibility, Target, Web of Science, X-Ray, Xpd, Xrcc1

? Wu, B., Guo, D. and Guo, Y. (2014), Association between p53 Arg72Pro polymorphism and thyroid cancer risk: A meta-analysis. Tumor Biology, 35 (1), 561-565.

Full Text: 2014\Tum Bio35, 561.pdf

Abstract: the p53 is a tumor suppressor gene which may be involved in the development of thyroid cancer. Studies investigating the association between p53 Arg72Pro polymorphism and thyroid cancer risk reported conflicting results. The aim of the meta-analysis was to derive a more precise assessment of the association between p53 Arg72Pro polymorphism and thyroid cancer risk. A literature search of PubMed and Web of Science from their inception through March 2013 was conducted. Odds ratios (OR) with 95 % confidence intervals (95 % CI) were used to assess the strength of the association. Eight case-control studies were included with a total of 874 thyroid cancer cases and 1,891 controls. The meta-analysis results showed that the p53 Arg72Pro polymorphism was only associated with thyroid cancer risk under the recessive model (ProPro vs. ArgArg/ArgPro: OR = 1.83, 95 % CI 1.05-3.20, P = 0.034). However, there was no significant association between p53 Arg72Pro polymorphism and thyroid cancer risk under the other three genetic models (Pro vs. Arg: OR = 1.20, 95 % CI 0.87-1.67, P = 0.262; ProPro vs. ArgArg: OR = 1.75, 95 % CI 0.88-3.50, P = 0.113; ProPro/ArgPro vs. ArgArg: OR = 1.01, 95 % CI 0.66-1.55, P = 0.968). Subgroup by ethnicity showed that there was no significant association between p53 Arg72Pro polymorphism and thyroid cancer risk in both Caucasians and Asians. Thus, p53 Arg72Pro polymorphism may be associated with thyroid cancer risk, and ProPro genotype is likely to be a risk factor of thyroid cancer.

Keywords: Assessment, Association, Cancer, Carcinoma, Case-Control, Case-Control Studies, Codon-72, Confidence, Confidence Intervals, Cyp1a1, Development, Ethnicity, Gene, Genes, Genetic, Intervals, Literature, Literature Search, Mechanisms, Meta Analysis, Meta-Analysis, Metaanalysis, Model, Models, P, P53, Pathogenesis, Polymorphism, Proline, Pubmed, Risk, Risk Factor, Science, Strength, Susceptibility, Thyroid Cancer, Tumor, Web of Science

? Gao, S., Ma, J.J. and Lu, C. (2014), Venous thromboembolism risk and erythropoiesis-stimulating agents for the treatment of cancer-associated anemia: A meta-analysis. Tumor Biology, 35 (1), 603-613.

Full Text: 2014\Tum Bio35, 603.pdf

Abstract: Erythropoiesis-stimulating agents (ESAs) reduce anemia in patients with cancer and could improve their quality of life, but ESA-related safety concerns exist. To evaluate the overall risk of venous thromboembolism (VTE) associated with the use of ESAs, a systematic review and meta-analysis of published randomized controlled trials (RCTs) was performed. The databases of PubMed and Web of Science and the abstracts presented at the American Society of Clinical Oncology conferences were searched to identify relevant clinical trials. Summary incidence rates, relative risks (RRs), and 95 % confidence intervals (CIs) were calculated. A total of 12,115 patients with a variety of cancer types from 51 RCTs were identified and included in the meta-analysis. Among patients receiving ESAs, the summary incidence of all-grade VTE was 7.78 %. Patients with cancer who received ESAs had increased VTE risks (484 events among 6,301 patients treated with ESA vs. 276 events among 5,814 control patients; RR = 1.75 [95 % CI, 1.50-2.05]). The highest risk of VTE was found in patients with ovarian and cervical cancers (RR = 2.45 [CI = 1.12-5.33]). The VTE risk among hematologic malignancies was higher than that among solid tumors. The administration of ESAs was significantly associated with an increased risk of developing VTE in cancer patients receiving these drugs. The risks of VTE may vary with various tumor types, including hematologic malignancies.

Keywords: Administration, Anemia, Cancer, Cell Lung-Cancer, Chemotherapy-Induced Anemia, Clinical, Clinical Trials, Conferences, Confidence, Confidence Intervals, Control, Darbepoetin, Darbepoetin-Alpha, Databases, Developing, Double-Blind, Drugs, Epoetin-Alpha, Erythropoiesis-Stimulating Agents, Erythropoietin, Events, Hematologic, Incidence, Intervals, Life, Meta Analysis, Meta-Analysis, Metaanalysis, Oncology, Patients, Patients Receiving Chemotherapy, Phase-Iii Trial, Placebo-Controlled Trial, Platinum-Based Chemotherapy, Pubmed, Quality, Quality Of, Quality of Life, Randomized, Randomized Controlled Trials, Rates, Recombinant-Human-Erythropoietin, Review, Risk, Risks, Safety, Science, Systematic Review, Thromboembolism, Treatment, Tumor, Venous Thromboembolism, Web of Science

? Duan, C.Y., Liu, M.Y., Li, S.B., Ma, K.S. and Bie, P. (2014), Lack of association of EPHX1 gene polymorphisms with risk of hepatocellular carcinoma: A meta-analysis. Tumor Biology, 35 (1), 659-666.

Full Text: 2014\Tum Bio35, 659.pdf

Abstract: Previous studies have focused on the association of a gene (EPHX1) encoding microsomal epoxide hydrolase with the carcinogenesis of hepatocellular carcinoma (HCC). In the present study, we performed a meta-analysis to systematically summarize the possible association between EPHX1 genetic polymorphisms and the risk for HCC. We conducted a search of case-control studies on the associations of EPHX1 genetic polymorphisms with susceptibility to HCC in PubMed, EMBASE, ISI Web of Science, Wanfang database in China, and the Chinese National Knowledge Infrastructure databases. Data from eligible studies were extracted for meta-analysis. HCC risk associated with EPHX1 genetic polymorphism was estimated by pooled odds ratios and 95 % confidence intervals. Thirteen studies were included in the present meta-analysis. Our results showed that, for the two polymorphisms (337 T > C and 416A > G) of EPHX1 gene, neither allele frequency nor genotype distributions were associated with risk for HCC in all genetic models (all P > 0.05). This meta-analysis suggests that EPHX1 genetic polymorphisms were not associated with the risk of HCC.

Keywords: Association, Carcinoma, Case-Control, Case-Control Studies, China, Chinese, Confidence, Confidence Intervals, Database, Databases, Embase, Epoxide, Gene, Genetic, Genetic Polymorphisms, Glutathione-S-Transferase, Hepatocellular Carcinoma, Intervals, ISI, ISI Web of Science, Knowledge, Liver-Disease, Meta Analysis, Meta-Analysis, Metaanalysis, Microsomal Epoxide Hydrolase, Microsomal Epoxide Hydrolase, Models, P, Polymorphism, Polymorphisms, Population, Pubmed, Risk, Science, Susceptibility, Web of Science

? Song, N., Liu, B., Wu, J.L., Zhang, R.F., Duan, L., He, W.S. and Zhang, C.M. (2014), Vascular endothelial growth factor (VEGF)-2578C/A and -460C/T gene polymorphisms and lung cancer risk: A meta-analysis involving 11 case-control studies. Tumor Biology, 35 (1), 859-870.

Full Text: 2014\Tum Bio35, 859.pdf

Abstract: the aim of this meta-analysis is to generate large-scale evidence on whether common vascular endothelial growth factor (VEGF) gene polymorphisms (-2578C/A [dbSNP: rs699947] and -460C/T [dbSNP: rs833061]) are associated with lung cancer. A literature search of PubMed, Embase, Web of Science, Cochrane Library, and CBM databases was conducted to identify all eligible studies published before May 3, 2013. Crude odds ratios (ORs) with their corresponding confidence intervals (95 % CIs) were used to evaluate the strength of the association. Eleven case-control studies were included with a total of 3,861 lung cancer cases and 3,676 controls in this meta-analysis. For the VEGF -2578C/A polymorphism, the combined results showed that there exist highly significant risk factors for individuals carrying the A allele resulting in lung cancer, and the magnitude of this effect was similar in smoker patients and squamous cell carcinoma (SCC) patients. Unlike the situation with the -2578C/A polymorphism, the VEGF -460C/T polymorphism is not associated with the risk of lung cancer in neither Asians nor Caucasians. However, when stratified according to smoking status and histological types of lung cancer, we found that the T allele (-460C/T) was associated with decreased lung cancer risk among nonsmoker patients and SCC patients. Our findings showed that the -2578C/A polymorphism may increase lung cancer risk, especially in smoker patients and SCC patients, whereas the -460C/T polymorphism may decrease lung cancer risk, especially in nonsmoker patients and SCC patients.

Keywords: Angiogenesis, Association, Bevacizumab, Breast-Cancer, Cancer, Carcinoma, Case-Control, Case-Control Studies, Colorectal-Cancer, Confidence, Confidence Intervals, Databases, Evidence, Expression, Factor Vegf, Gene, Growth, Growth Factor, Heterogeneity, Inhibition, Intervals, Literature, Literature Search, Lung, Lung Cancer, Magnitude, Meta Analysis, Meta-Analysis, Metaanalysis, Patients, Polymorphism, Polymorphisms, Prognosis, Pubmed, Risk, Risk Factors, Science, Smoking, Squamous Cell Carcinoma, Strength, Tumor-Growth, Vascular Endothelial Growth Factor, VEGF, Web of Science

? Shi, D.T., Han, M., Gao, N., Tian, W.Y. and Chen, W.C. (2014), Association of RASSF1A promoter methylation with gastric cancer risk: A meta-analysis. Tumor Biology, 35 (2), 943-948.

Full Text: 2014\Tum Bio35, 943.pdf

Abstract: Ras-association domain family 1A (RASSF1A), a candidate tumor suppressor gene, is frequently silenced and inactivated by hypermethylation of its promoter region in several human tumors. However, the association between RASSF1A promoter methylation and gastric cancer risk remains conflicting. The aim of this study was to assess the association of RASSF1A promoter methylation with gastric cancer risk by a comprehensive meta-analysis. Relevant studies were identified by searches of PubMed and Web of Science databases with no restrictions. Combined odds ratio (OR) and 95 % confidence interval (CI) were used to assess the strength of the association between RASSF1A promoter methylation and gastric cancer risk. A chi-square-based Q test and sensitivity analyses were performed to test the between-study heterogeneity and the contributions of single studies to the final results, respectively. Funnel plots were carried out to evaluate publication bias. Overall, a significant association was observed between RASSF1A promoter methylation and gastric cancer risk (OR, 12.67; 95 % CI, 8.12-19.78; p < 0.001) with no between-study heterogeneity. Subgroup analyses further revealed that gastric cancer risk was increased for individuals carrying the methylated RASSF1A compared with those with unmethylated RASSF1A. In addition, no publication bias was detected in the overall and subgroup analyses. This study identified a strong association between RASSF1A promoter methylation and risk of gastric cancer and highlighted a promising potential for RASSF1A promoter methylation in gastric cancer risk prediction.

Keywords: Adenocarcinoma, Analyses, Association, Bias, Cancer, Cancer Risk, Carcinogenesis, China, Confidence, Cpg Island Methylation, Databases, Dna Methylation, Epigenetic Inactivation, Family, Gastric, Gastric Cancer, Gene, Heterogeneity, Human, Hypermethylation, Interval, Meta Analysis, Meta-Analysis, Metaanalysis, Methylation, Odds Ratio, Potential, Prediction, Profile, Publication, Publication Bias, Pubmed, Rassf1a, Region, Restrictions, Risk, Science, Sensitivity, Strength, Suppressor, Tumor, Tumor Suppressor Gene, Tumor-Related Genes, Web of Science, Web of Science Databases

? Huang, O., Jiang, M., Zhang, X., Chen, X.S., Wu, J.Y. and Shen, K.W. (2014), FASLG T844C polymorphism and susceptibility to breast cancer: A meta-analysis. Tumor Biology, 35 (2), 1089-1094.

Full Text: 2014\Tum Bio35, 1089.pdf

Abstract: Many studies were published to assess the association between FASLG T844C polymorphism and susceptibility to breast cancer, but the data were controversial. A meta-analysis was performed to assess the association comprehensively. We performed a comprehensive search in PubMed, Embase, and Web of Science to find eligible studies. Six studies with a total of 6,784 participants were finally included into the meta-analysis. There were a total of 3,382 cases with breast cancer and 3,402 controls in those six studies. Odds ratio (OR) with 95 % confidence interval (95 %CI) was used to evaluate the association. Overall, there was an obvious association between FASLG T844C polymorphism and breast cancer under all four contrast models (for C versus T: OR = 1.26, 95 %CI 1.05-1.50, P (OR) = 0.011; for CC versus TT: OR = 1.42, 95 %CI 1.11-1.81, P (OR) = 0.005; for CC versus TT/TC: OR = 1.41, 95 %CI 1.06-1.88, P (OR) = 0.019; for CC/TC versus TT: OR = 1.16, 95 %CI 1.01-1.33, P (OR) = 0.038). In the subgroup analysis by ethnicity, there was an obvious association between FASLG T844C polymorphism and breast cancer in Asians, but there was no obvious association in Caucasians. The meta-analysis suggests that there is an association between FASLG T844C polymorphism and susceptibility to breast cancer, especially in Asians.

Keywords: Analysis, Apoptosis, Association, Breast Cancer, Cancer, Carcinoma, Confidence, Data, Disease, Ethnicity, Faslg, Interval, Meta Analysis, Meta-Analysis, Metaanalysis, Models, P, Pathway Genes Fas, Polymorphism, Pubmed, Risk, Science, Web of Science

? Liu, C., Yin, Q.H., Hu, J.B., Weng, J. and Wang, Y.J. (2014), Quantitative assessment of the association between XPG Asp1104His polymorphism and bladder cancer risk. Tumor Biology,